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ORIGINAL INVESTIGATION
Associations of coronary artery calcified 
plaque density with mortality in type 2 diabetes: 
the Diabetes Heart Study
Laura M. Raffield1,2,3*, Amanda J. Cox2,3,4, Michael H. Criqui5, Fang‑Chi Hsu2,6, James G. Terry7, Jianzhao Xu2,3, 
Barry I. Freedman8, J. Jeffrey Carr7 and Donald W. Bowden2,3,9
Abstract 
Background: Coronary artery calcified plaque (CAC) is strongly predictive of cardiovascular disease (CVD) events 
and mortality, both in general populations and individuals with type 2 diabetes at high risk for CVD. CAC is typically 
reported as an Agatston score, which is weighted for increased plaque density. However, the role of CAC density in 
CVD risk prediction, independently and with CAC volume, remains unclear.
Methods: We examined the role of CAC density in individuals with type 2 diabetes from the family‑based Diabetes 
Heart Study and the African American‑Diabetes Heart Study. CAC density was calculated as mass divided by vol‑
ume, and associations with incident all‑cause and CVD mortality [median follow‑up 10.2 years European Americans 
(n = 902, n = 286 deceased), 5.2 years African Americans (n = 552, n = 93 deceased)] were examined using Cox pro‑
portional hazards models, independently and in models adjusted for CAC volume.
Results: In European Americans, CAC density, like Agatston score and volume, was consistently associated with 
increased risk of all‑cause and CVD mortality (p ≤ 0.002) in models adjusted for age, sex, statin use, total cholesterol, 
HDL, systolic blood pressure, high blood pressure medication use, and current smoking. However, these associations 
were no longer significant when models were additionally adjusted for CAC volume. CAC density was not significantly 
associated with mortality, either alone or adjusted for CAC volume, in African Americans.
Conclusions: CAC density is not associated with mortality independent from CAC volume in European Americans 
and African Americans with type 2 diabetes.
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Background
Many studies have found computed tomography (CT)-
based measures of calcified plaque in the coronary 
arteries (CAC) to be predictive of cardiovascular dis-
ease (CVD) events and mortality, independent from 
traditional CVD risk factors [1–5]. CAC is also a pow-
erful independent risk factor for CVD and mortality 
in individuals with type 2 diabetes (T2D) [6–9], with 
elevated CAC burden in diabetic patients compared to 
non-diabetic individuals [10]. This is of particular inter-
est due to the elevated CVD risk in individuals with T2D, 
with mortality risk from CVD increased two- to fourfold 
and approximately 68% of T2D-affected individuals age 
65 or older succumbing to CVD [11].
Recent work from the Multi-Ethnic Study of Athero-
sclerosis (MESA) found that increased CAC density, in 
models adjusted for plaque volume, was associated with 
a decreased risk of coronary heart disease (CHD) events 
(HR of 0.73, 95% CI 0.58–0.91 per standard deviation 
increase) and all CVD events, with improved risk pre-
diction for CHD and CVD events with the inclusion of 
density [12]. These results were contrary to the assump-
tions of using Agatston scores to assess CAC, as those 
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scores are weighted for increased density [13, 14], and the 
results have been confirmed in re-analysis of the MESA 
dataset with additional events from 11 years median fol-
low-up [15]. Further study of the role of calcified plaque 
density in CVD risk appears to be warranted. We evalu-
ated the associations of CAC density measures with 
incident mortality in a high risk population with T2D, 
including participants of both European American (EA) 
and African American (AA) descent from the Diabe-
tes Heart Study (DHS) and African American-Diabetes 
Heart Study (AA-DHS).
Methods
Study design and sample
The DHS recruited T2D-affected siblings without 
advanced renal insufficiency, as well as their unaffected 
siblings when possible, from outpatient internal medi-
cine and endocrinology clinics at Wake Forest Baptist 
Medical Center and from the community from 1998 
through 2005; this initial DHS cohort included 1221 
self-reported EA individuals and 222 self-reported AA 
participants. Differences in the distribution of vascular 
calcification between EA and AA participants, with AA 
participants generally having lower vascular calcification 
burden despite higher levels of traditional CVD risk fac-
tors [16], an observation supported by many additional 
studies [17–19], prompted the development of the inde-
pendent AA-DHS Study. AA-DHS recruited additional 
unrelated African American participants with T2D from 
2007 to 2010. Recruitment criteria and objectives of the 
DHS family of studies have been reported [20]. T2D was 
defined in DHS studies as diabetes developing after the 
age of 35 years (or after the age of 30 in AA participants) 
initially treated with changes in diet and exercise and/
or oral agents, in the absence of historical evidence of 
ketoacidosis or initial treatment with insulin. Individuals 
with prior evidence of CVD were included. Fasting glu-
cose and glycated hemoglobin  (HbA1C) concentrations 
were assessed at the exam visit.
Participant examinations for the DHS and AA-DHS 
included interviews for medical history and health 
behaviors, anthropometric measures, resting blood pres-
sure, electrocardiography, fasting blood sampling for lab-
oratory analyses, and spot urine collection. As described, 
CAC was assessed using CT, summing the left main, left 
anterior descending, circumflex, posterior descending, 
and right coronary arteries [21–23]. CT scans were per-
formed on multi-detector CT scanners with cardiac gat-
ing in chest scans, with a CT slice thickness of 2.5  mm 
for AA-DHS and 2.5 or 3  mm, depending on the scan-
ner used, for DHS. The protocol for CAC imaging was 
the same as in two large population-based studies of sub-
clinical cardiovascular disease, MESA and the Coronary 
Artery Risk Development in Young Adults (CARDIA) 
Study [24–26]; however, the DHS used the FDA approved 
and validated GE Healthcare Smartscore software pro-
gram, improving assessment of mass scores.
Mortality was assessed using the National Social Secu-
rity Death Index. When possible, copies of death certifi-
cates were obtained from county or state Vital Records 
Offices to determine cause of death. Cause of death was 
categorized based on death certificates as CVD mortality 
[myocardial infarction (MI), congestive heart failure, car-
diac arrhythmia, sudden cardiac death, peripheral vascu-
lar disease, and stroke] or as mortality from other causes. 
However, for 15 EA participants and 8 AA participants, 
information on cause of death could not be obtained; 
these 23 participants were excluded from analyses of 
CVD mortality. For deceased participants, length of 
follow-up was determined from the date of initial study 
visit to date of death. For all other participants the length 
of follow-up was determined from the date of the initial 
study visit to December 31, 2013.
For our main analysis, we included only individuals 
affected by T2D with non-missing covariate data and 
non-zero values for the relevant CAC values at the 90 
Hounsfield unit (HU) threshold, which is more sensitive 
but less specific than the frequently used 130 HU thresh-
old. This included a total of 902 EA participants from 448 
families from the DHS and 552 AA participants from 483 
families from the DHS and AA-DHS, including 139 indi-
viduals from 70 families from the DHS and 413 unrelated 
individuals from the AA-DHS. A supplemental analy-
sis of 816 EA participants and 446 AA participants with 
non-zero Agatston scores at the 130 HU threshold was 
also performed.
Statistical analysis
Associations were examined for five measures of calci-
fied plaque burden, including volume, Agatston score 
at the 90 HU and 130 HU thresholds, and two density 
measures. The density measure used in all main analyses 
was calculated by dividing mass over volume. As a sup-
plemental analysis, an alternate density measure calcu-
lated as Agatston score over plaque area (calculated as 
volume divided by CT slice thickness, which was either 
2.5 or 3  mm depending on the scanner used) was ana-
lyzed. This alternate density measure is similar to the 
measure analyzed in MESA, which did not have access 
to reliable mass scores [12]. Some plaque measures were 
transformed prior to analysis. In EA and AA partici-
pants, volume and Agatston scores were ln transformed 
and the alternate density measure calculated as Agatston 
divided by area was squared to better approximate a nor-
mal distribution (Additional file  1: Figure S1). Untrans-
formed summary statistics are presented in Table  1. 
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Non-parametric Spearman correlation coefficients were 
calculated to determine relationships between these cal-
cified plaque measures.
Associations with incident all-cause and CVD mor-
tality were assessed using Cox proportional hazards 
models with sandwich-based variance estimation, due 
to the family structure of the DHS cohort. Models 
were adjusted for age, sex, study (DHS and AA-DHS, 
for AA participants only), statin use, ln transformed 
total cholesterol, square root transformed high-density 
lipoprotein cholesterol (HDL), systolic blood pressure 
(SBP), high blood pressure medication use, and cur-
rent smoking. A minimally adjusted model (adjusted 
for age, sex, and, in African Americans, study only) was 
also assessed; results were similar and are not shown. 
As a supplemental analysis, self-reported prior CVD 
events were examined using marginal models with gen-
eralized estimating equations with a sandwich estima-
tor of the variance under exchangeable correlation. For 
self-reported prior CVD, we analyzed (a) self-reported 
history of MI, and (b) a composite measure including 
MI, angina, or stroke, history of vascular procedures 
including coronary angioplasty, coronary artery bypass 
graft, or endarterectomy, or Q wave abnormalities 
indicative of prior MI using the Minnesota code. All 
analyses were performed in SAS 9.3.
Table 1 Demographic characteristics of  European American and  African American participants with  type 2 diabetes 
from  the  Diabetes Heart Study and  African American Diabetes-Heart Study cohorts with  non-zero coronary artery 
calcification burden and complete covariate data for analysis models
CAC coronary artery calcified plaque, HU Hounsfield unit
Trait European Americans (n = 902) African Americans (n = 552)
Mean (SD) or % Median (range) n Mean (SD) or % Median (range) N
Age (years) 62.8 (9) 63.3 (34.2, 86) 902 57.4 (9.3) 57.5 (35, 86) 552
Female sex (%) 50.4 902 59.8 552
Current smoking (%) 16.5 902 23.9 552
Past smoking (%) 43.6 902 36.8 552
History of myocardial infarction (%) 22.4 894 11.9 547
History of cardiovascular disease (%) 44.7 894 35.7 526
Incident all‑cause mortality (%) 31.7 902 16.9 552
Incident cardiovascular disease mortality (%) 14.9 887 7.7 544
Follow‑up time (years) 9.5 (3.1) 10.2 (0.3, 15.6) 902 6 (3) 5.2 (0.3, 16) 552
Body mass index (kg/m2) 32.3 (6.5) 31.3 (17.1, 58) 902 35.3 (8.2) 34 (17.1, 77.5) 552
Glucose (mg/dL) 148.2 (56.2) 135.5 (16, 463) 900 149.6 (65.3) 134 (32, 524) 552
Glycated hemoglobin (%) 7.5 (1.6) 7.2 (4.6, 16.6) 896 8.2 (2.1) 7.7 (4.4, 21.8) 543
Glycated hemoglobin (mmol/mol) 59 (17.7) 55.2 (26.8, 157.9) 896 66.2 (23.2) 60.7 (24.6, 214.8) 543
Diabetes duration (years) 10.6 (7.2) 8 (0, 46) 888 10.7 (7.9) 8.5 (0, 52) 552
CAC mass score (mg, 90 HU) 1960 (3414) 562 (0.5, 50,415) 889 1028 (2025) 161 (1, 15,527) 552
CAC volume score  (mm3, 90 HU) 899 (1328) 361 (1, 15,569) 902 432 (784) 90 (1, 6103) 552
CAC Agatston score (90 HU) 1031 (1640) 365 (0.5, 20,563) 901 497 (956) 82 (0.5, 7502) 551
CAC Agatston score (130 HU) 828 (1277) 331 (0.5, 16,287) 816 446 (772) 110 (0.5, 5693) 446
CAC density (mg/mm3, 90 HU) 1.71 (0.76) 1.74 (0.02, 4.46) 889 1.8 (0.65) 1.75 (0.9, 5.39) 552
Alternate CAC density (Agatston score/area, 
Hounsfield unit category units, 90 HU)
2.25 (0.83) 2.51 (0.63, 4.29) 901 2.09 (0.87) 2.35 (0.5, 3.42) 551
Total cholesterol (mg/dL) 184.5 (43.1) 180 (65, 391) 902 183.5 (45.6) 178 (81, 428) 552
HDL (mg/dL) 42.3 (12) 41 (8, 98) 902 48.3 (14) 46 (18, 115) 552
Systolic blood pressure (mmHg) 140 (19.1) 138.5 (94, 260) 902 136.7 (19.4) 134.3 (85, 211) 552
Diastolic blood pressure (mmHg) 72.3 (10.2) 71.5 (36.5, 106) 902 77.3 (11.6) 77 (48.5, 122) 552
High blood pressure medications (%) 76.4 902 84.1 552
Statin use (%) 43.8 902 49.5 552
Oral hypoglycemic medications (%) 79.5 902 76.3 552
Insulin use (%) 27.5 902 42.2 552
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Results
Demographic characteristics of AA and EA participants 
in the DHS and AA-DHS included in calcified plaque 
density analyses are summarized in Table  1. Mean dia-
betes duration was 10.6 ± 7.2  years [mean ± standard 
deviation (SD)] in EA participants and 10.7 ± 7.9  years 
in AA participants. 44.7% of EA participants and 35.7% 
of AA participants had a history of CVD, and mean BMI 
was > 30 kg/m2 in both groups. While burden of subclini-
cal CVD was extensive in both groups, EA participants 
had higher median calcified plaque volume (361) than 
AA participants (90), consistent with prior reports [16–
18]. Using a 90 HU threshold, there were 901 EA partici-
pants with a non-zero Agatston score (median 365) and 
551 AA participants with a non-zero score (median 82); 
as expected, fewer individuals had a non-zero Agatston 
score at the less sensitive but more specific 130 HU 
threshold, with 816 EA participants with a non-zero 
Agatston score (median 331) and 446 AA participants 
with a non-zero score (median 110). Incident all-cause 
mortality was greater for EA participants (31.7%) than 
AA participants (16.9%) as well, likely in part due to 
longer follow-up time in EA participants.
In both EA (Additional file 1: Table S1) and AA (Addi-
tional file  1: Table  S2) participants, the CAC measures 
are highly correlated, with volume and Agatston score at 
the 90 HU and 130 HU threshold very highly correlated 
in both groups (r > 0.95). Volume and Agatston score 
measures were also significantly correlated with density 
in AA and in EA participants (r > 0.66).
In EA participants (Table 2), all CAC measures, includ-
ing volume, Agatston scores at both the 90 HU and 
130 HU thresholds, and density, were associated with 
increased risk of all-cause and CVD mortality (p ≤ 0.002) 
in models adjusted for age, sex, statin use, total choles-
terol, HDL, SBP, high blood pressure medication use, 
and current smoking. When density and volume meas-
ures were included in the same model (Table 3), plaque 
volume remained consistently associated with elevated 
mortality (p ≤ 3.70 × 10−4), but associations with plaque 
density were attenuated to non-significance (p ≥ 0.252). 
In the smaller AA sample, plaque volume and Agatston 
scores were associated with elevated risk of all-cause and 
CVD mortality (p ≤ 0.046), but plaque density was not 
significantly associated with mortality risk (p ≥ 0.106) 
(Table 2). Similar to EAs, in models including both den-
sity and volume measures, volume was associated with 
elevated mortality risk in AAs (p ≤ 0.003), but no signifi-
cant association with density was observed (p ≥ 0.117) 
(Table 3).
As a supplementary analysis, we also analyzed asso-
ciations of CAC measures with self-reported history 
of CVD and MI. In EA participants, all CAC measures, 
including density, were associated with higher odds of 
having a history of CVD and MI events (p ≤ 4.65 × 10−6), 
with similar results in AA participants (p ≤ 1.84 × 10−4) 
(Additional file  1: Table  S3). With density and volume 
measures included in the same model, in EA participants 
both volume and density were associated with higher 
odds of prior CVD and MI (p ≤ 0.046); trends were simi-
lar but density was not significantly associated in AA par-
ticipants (Additional file 1: Table S4).
Finally, to increase comparability of our results with 
the prior analysis of calcified plaque density in the MESA 
Table 2 Associations with incident all-cause and cardiovascular disease (CVD) mortality for coronary artery calcification 
measures analyzed in  independent models in  European American and  African American participants with  type 2 
diabetes
Hazard ratios for mortality associations reported per standard deviation change in coronary artery calcification measures. Models adjusted for age, sex, statin use, 
total cholesterol, HDL, systolic blood pressure, high blood pressure medication use, and current smoking; analyses additionally adjusted for study (Diabetes Heart 
Study or African American Diabetes Heart Study) in African Americans
HU Hounsfield unit
Outcome CAC measure European Americans African Americans
Hazard ratio 95% 
confidence 
interval
p-value n Hazard ratio 95% 
confidence 
interval
p-value n
All‑cause mortality Volume (90 HU) 1.67 1.37 2.03 3.08 × 10−7 902 1.48 1.14 1.92 0.003 552
All‑cause mortality Agatston score (90 HU) 1.65 1.35 2.02 1.02 × 10−6 901 1.45 1.12 1.88 0.005 551
All‑cause mortality Agatston score (130 HU) 1.54 1.27 1.87 1.42 × 10−5 816 1.27 1.01 1.61 0.046 446
All‑cause mortality Density (90 HU) 1.31 1.12 1.53 6.98 × 10−4 889 1.13 0.92 1.38 0.233 552
CVD mortality Volume (90 HU) 1.93 1.45 2.57 6.58 × 10−6 887 2.00 1.25 3.21 0.004 544
CVD mortality Agatston score (90 HU) 1.86 1.39 2.49 3.46 × 10−5 886 1.98 1.25 3.13 0.004 543
CVD mortality Agatston score (130 HU) 1.68 1.25 2.27 5.74 × 10−4 801 1.84 1.20 2.84 0.006 438
CVD mortality Density (90 HU) 1.39 1.13 1.70 0.002 875 1.26 0.95 1.66 0.106 544
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cohort [12], we repeated our analyses with an alternate 
measure of plaque density (Agatston score over area), 
which was derived in MESA as reliable mass measure-
ments were unavailable. Results were broadly similar; 
higher density was associated with higher CVD mortality 
and higher odds of history of CVD and MI in EA and AA 
participants (p ≤ 0.014), as well as with higher all-cause 
mortality in EAs (p = 9.62 × 10−6) (Additional file  1: 
Table  S5). Adjusting for volume, no significant asso-
ciations with this alternate density measure remained 
(Additional file 1: Table S6).
Discussion
The utility of CAC, usually assessed using Agatston or 
volume measures, in predicting CVD events and mor-
tality is well-established in the general population [1–5] 
and in those with T2D [6–9]. Questions remain concern-
ing whether CAC plaque density adds to the predictive 
power of CAC volume. This analysis from the DHS in 
both EA and AA participants with T2D assessed asso-
ciations of multiple CAC measures, including plaque 
volume, Agatston scores, and density, with incident mor-
tality. We found that all of these CAC measures, includ-
ing density, were associated higher risk of all-cause and 
CVD mortality in EA participants. In models adjusted 
for volume, however, no independent associations with 
density measures remained. Results were broadly simi-
lar in AA participants, though no association of density 
unadjusted for volume with mortality risk was observed. 
These results do not suggest a consistent association of 
CAC density with mortality independent of volume in 
patients with T2D.
While our results do not suggest an independent rela-
tionship of calcified plaque density with mortality, fur-
ther study is needed to assess how the characteristics 
of calcified and non-calcified plaque may contribute to 
CVD risk. Our scans are done with non-contrast CT 
and we can comment on characteristics such as density 
for calcified plaque only, not the non-calcified portions; 
total coronary plaque area is generally ~ 5 times greater 
than calcified plaque area [27]. We did not assess more 
specific plaque characteristics such as the fibrous cap 
thickness or consider differential mortality risk based on 
characteristics such as lesion number and location in the 
coronary arteries [28]. Further understanding of plaque 
characteristics in multiple patient populations, includ-
ing those with diabetes, may also help evaluate the use-
fulness of alternate calcified plaque scoring methods and 
density calculations [29–32], which may have advantages 
over the Agatston method in certain clinical and research 
settings (such as increased speed in CAC assessment 
[32, 33], or increased sensitivity for detecting very small 
plaques [29]). Plaque characteristics, as opposed to sim-
ply total plaque, may also modify observed associations 
with CVD events. In individuals with diabetes [34], as 
well as other patient populations [35, 36], some reports 
suggest that very high CAC scores, which may represent 
larger, denser plaques, are associated with increased risk 
of more stable CVD phenotypes (such as angina) versus 
sudden death or MI; however, in our population, previ-
ous work has shown very high mortality rates in individu-
als with T2D and CAC > 1000 [37], suggesting substantial 
CVD burden in this population. Further study is needed 
to determine what levels of CAC and CAC characteristics 
are associated with particular CVD events, particularly in 
individuals with T2D.
Results in the DHS differ from those previously 
observed in MESA, in which the largest existing 
multi-ethnic study of CAC plaque density was per-
formed. Calcified plaque density unadjusted for vol-
ume was not predictive of CHD or CVD events in 
MESA, but, when models included both CAC volume 
and CAC density, increased plaque density was asso-
ciated with a decreased risk of CHD and CVD events 
[12]. In the DHS, calcified plaque density unadjusted 
for volume was predictive of higher mortality risk (in 
Table 3 Associations with  incident all-cause and  cardiovascular disease (CVD) mortality for  density and  volume 
measures analyzed in the same model in European American and African American participants with type 2 diabetes
Hazard ratios for mortality associations reported per standard deviation change in coronary artery calcification measures. Models adjusted for age, sex, statin use, 
total cholesterol, HDL, systolic blood pressure, high blood pressure medication use, and current smoking; analyses additionally adjusted for study (Diabetes Heart 
Study or African American Diabetes Heart Study) in African Americans. All calcification measures were derived using a 90 HU (Hounsfield unit) threshold
Outcome CAC measure European Americans African Americans
Hazard ratio 95% 
confidence 
interval
p-value n Hazard ratio 95% 
confidence 
interval
p-value n
All‑cause mortality Volume 1.60 1.29 1.99 2.25 × 10−5 889 1.76 1.22 2.53 0.003 552
Density 1.10 0.94 1.28 0.225 889 0.77 0.55 1.07 0.117 552
CVD mortality Volume 1.78 1.30 2.44 3.70 × 10−4 875 2.56 1.40 4.67 0.002 544
Density 1.13 0.92 1.39 0.252 875 0.69 0.43 1.10 0.121 544
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EA participants); however, in models adjusted for vol-
ume, plaque density was not associated with mortality. 
There was a non-significant trend towards reduced risk 
of all-cause and CVD mortality with increased density 
in models adjusted for volume in African Americans, 
which would be concordant with the MESA results.
A number of differences exist between our analysis 
of the DHS and AA-DHS studies and the analysis in 
MESA. Most notably, our study was limited to partici-
pants with T2D, while MESA included only 17.9% T2D-
affected participants. However, there was no significant 
interaction for diabetes in the most recent MESA anal-
ysis of density adjusted for volume [15]. The DHS is 
characterized by a high average burden of CAC, with 
a mean CAC Agatston score at the 130 HU threshold 
of 828 in EA participants and 446 in AA participants, 
compared to a mean CAC Agatston score of 293 for 
MESA participants, which recruited individuals free 
of clinical CVD at baseline. MESA had relatively low 
rates of statin use in those with non-zero CAC (20.1% 
of participants), likely due to lack of clinical CVD at 
baseline, while many EA and AA DHS participants 
reported a history of clinical CVD at baseline (> 35% in 
both groups), and statin use was higher (> 40%). Statin 
use may impact the differing relationships of CAC den-
sity and CVD in DHS and MESA, though both analyses 
did adjust for statin use; some studies indicate statins 
may increase CAC progression [38] and may impact 
CAC density, for example by reducing low attenuation 
plaque volume [39, 40]. A recent analysis from MESA 
suggested that statin use may attenuate the association 
between calcified plaque density and incident CVD 
in those with diabetes or metabolic syndrome [41]. 
We used a more intuitive mass over volume measure 
for density for our main analyses, though results were 
similar with an alternate density measure calculated as 
Agatston score over area (similar to that analyzed in 
MESA) in supplementary analyses. The Agatston score 
weighting of area is not based on a true measured den-
sity of each pixel, but instead incorporates a weighted 
measure from 1 to 4 based on the highest density pixel, 
limiting the interpretability of the Agatston/area esti-
mate [13]. Other differences include smaller sample 
size, stratification by self-reported ethnicity (supported 
by significant interactions between self-reported ances-
try and calcified plaque measures (p < 0.05) in joint 
models), higher correlation between density and vol-
ume (though no extreme collinearity problems (vari-
ance inflation factor > 4) were observed), and no data 
for incident events. We also acknowledge that inaccura-
cies in cause of death data from death certificates have 
been documented [42, 43]; under- or over-reporting 
by physicians may be a concern for our CVD mortality 
measure. It should be noted, however, that this ambigu-
ity is not present when assessing all-cause mortality.
Analyses in MESA used the less sensitive but slightly 
more specific [30] 130 HU threshold for CAC assess-
ment, as compared to use of a 90 HU threshold in the 
DHS cohorts, which may have contributed to different 
results between reports, as inclusion of more edge vox-
els at the 90 HU threshold can impact the measured area, 
volume, and density. As Agatston scores, but not volume 
and mass, were recorded in the DHS cohorts at both the 
130 and 90 HU thresholds, we attempted to address this 
difference by limiting our analysis of density, Agatston 
score, and volume measures from the 90 HU threshold 
to only those with a non-zero Agatston score at the 130 
HU threshold (n = 816 for EA participants, n = 446 for 
AA participants). Results were similar to the analysis in 
the full sample, with results displayed in Additional file 1: 
Tables S7 and S8. We ran similar models in European 
participants with all participants with an Agatston score 
less than 10 at the 130 HU threshold excluded. Again, 
results were similar, suggesting that small, potentially low 
density calcified plaques are not overly influencing our 
results.
Conclusions
In the T2D-affected DHS populations higher CAC 
plaque density was not consistently associated with risk 
of incident mortality in models adjusted for plaque vol-
ume. These results suggest that the role of CAC density 
may differ in the high CVD risk population of individu-
als affected by T2D; further study is needed to determine 
whether CAC density is independently predictive of CVD 
risk and its direction of effect in different patient popula-
tions. Longitudinal analyses of changes in CAC plaque 
density remain an important future goal.
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